Drug intelligence / Profile preview

AYK202

Development stage: Preclinical
Lead developer: Ayk Biotechnology
Modality: Small Molecules

Overview

AYK202 is a small molecule therapeutic candidate currently under development by AYK International (also known as AYK Bio) for the treatment of solid tumors. As of early 2024, the program is in the IND-enabling stage, with the company planning to submit an Investigational New Drug (IND) application in 2025. While the specific biological target and mechanism of action have not been publicly disclosed, the drug is part of AYK International's oncology pipeline, which focuses on developing novel treatments for various cancers.

Beyond the preview

Go deeper on AYK202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AYK202.

Explore the full profile